Showing results (141-150 of 148) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 148 results.
United European Gastroenterology Journal|July 28, 2020
The use of 5-aminosalicylate for patients with Crohn's disease in a prospective European inception cohort with 5 years follow-up - an Epi-IBD studyJohan Burisch, Daniel Bergemalm, Jonas Halfvarson, et al.
Journal of Crohn'S & Colitis|October 6, 2018
Natural Disease Course of Ulcerative Colitis During the First Five Years of Follow-up in a European Population-based Inception Cohort-An Epi-IBD StudyJohan Burisch, Konstantinos H Katsanos, Dimitrios K Christodoulou, et al.
The Lancet. Gastroenterology & Hepatology|February 17, 2020
Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based studyJohan Burisch, Hillel Vardi, Doron Schwartz, et al.
Inflammatory Bowel Diseases|December 2, 2014
Costs and resource utilization for diagnosis and treatment during the initial year in a European inflammatory bowel disease inception cohort: an ECCO-EpiCom StudyJohan Burisch, Hillel Vardi, Natalia Pedersen, et al.
Journal of Crohn'S & Colitis|June 3, 2017
Occurrence of Anaemia in the First Year of Inflammatory Bowel Disease in a European Population-based Inception Cohort-An ECCO-EpiCom StudyJohan Burisch, Zsuzsanna Vegh, Konstantinnos H Katsanos, et al.
JAMA|February 27, 2019
Association of Genetic Variants in NUDT15 With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel DiseaseGareth J Walker, James W Harrison, Graham A Heap, et al.
Journal of Crohn'S & Colitis|December 2, 2015
Clinical Features and HLA Association of 5-Aminosalicylate (5-ASA)-induced Nephrotoxicity in Inflammatory Bowel DiseaseGraham A Heap, Kenji So, Mike Weedon, et al.
Alimentary Pharmacology & Therapeutics|August 30, 2022
Implications for sequencing of biologic therapy and choice of second anti-TNF in patients with inflammatory bowel disease: results from the IMmunogenicity to Second Anti-TNF therapy (IMSAT) therapeutic drug monitoring studyNeil Chanchlani, Simeng Lin, Marcus K Auth, et al.
Pageof 15